Fenwick & West represented BioAge Labs, Inc. in the offering, and Cooley represented the underwriters. BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic...
You must be a Standard 1 Year member to access this content.
Fenwick & West is representing Smartsheet on the transaction, while Kirkland & Ellis and Simpson Thacher & Bartlett are representing Blackstone and Vista Equity Partners. Smartsheet...
You must be a Standard 1 Year member to access this content.
Fenwick & West advised Stoke Therapeutics on the offering, Wilson Sonsini Goodrich & Rosati advised Stoke on IP matters and Davis Polk & Wardwell advised the...
You must be a Standard 1 Year member to access this content.
Fenwick represented Third Harmonic Bio, Inc. on the deal. Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT...
You must be a Standard 1 Year member to access this content.
Fenwick & West LLP advised Impel NeuroPharma on the deal. Impel NeuroPharma, a late-stage pharmaceutical company developing transformative therapies for diseases of the central nervous system, announced its...
You must be a Standard 1 Year member to access this content.
Fenwick & West LLP advised AKASA on the deal. AKASA (formerly known as Alpha Health), the only Unified Automation™ company for revenue cycle management in healthcare,...
You must be a Standard 1 Year member to access this content.
Fenwick & West LLP advised Icertis on the deal. Icertis, a contract intelligence company that pushes the boundaries of what’s possible with contract lifecycle management, announced its...
You must be a Standard 1 Year member to access this content.
